eBulletin Newsletter

NCCN Flash Updates: NCCN Guidelines and NCCN Compendium Updated for Breast Cancer and More

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®), the NCCN Radiation Therapy Compendium™, and the NCCN Drugs and Biologics Compendium (NCCN Compendium^®) for Breast Cancer. These NCCN Guidelines^® are currently available as Version 4.2021.

Link directly to the Updates section of the NCCN Guidelines:
NCCN Guidelines for Breast Cancer

• Systemic Therapy Regimens for Recurrent Unresectable (local or regional) or Stage IV (M1) Disease
  • Footnote i added: An FDA-approved biosimilar is an appropriate substitute for bevacizumab. (BINV-Q 1 of 8)
  • Footnote n modified: Tucatinib + trastuzumab + capecitabine is preferred in patients with both systemic and CNS progression on ado-trastuzumab emtansine. However, tucatinib + trastuzumab + capecitabine may be given in the second-line setting. (BINV-Q 2 of 8)

Previous updates to the NCCN Guidelines for Breast Cancer can be found in the UPDATES section of the current version.

NCCN has published updates to the NCCN Guidelines and the NCCN Compendium^® for Soft Tissue Sarcoma. These NCCN Guidelines are currently available as Version 2.2021.

Link directly to the Updates section of the NCCN Guidelines:
NCCN Guidelines for Soft Tissue Sarcoma

• The following footnote has been added to the Systemic Therapy page for Angiosarcoma (SARC-F, 3 of 9) and Solitary Fibrous Tumor (SARC-F, 4 of 9).
  • An FDA-approved biosimilar is an appropriate substitute for:
    • Bevacizumab (footnote “k”)

Previous updates to the NCCN Guidelines for Soft Tissue Sarcoma can be found in the UPDATES section of the current version.

NCCN has published updates to the NCCN Guidelines and the NCCN Compendium for Head and Neck Cancers. These NCCN Guidelines are currently available as Version 3.2021.

Link directly to the Updates section of the NCCN Guidelines:
NCCN Guidelines for Head and Neck Cancers

• Systemic therapy for salivary gland tumors (SALI-B)
  • Footnote b added: An FDA-approved biosimilar is an appropriate substitute for trastuzumab.

Previous updates to the NCCN Guidelines for Head and Neck Cancers can be found in the UPDATES section of the current version.

NCCN has published updates to the NCCN Chemotherapy Order Templates (NCCN Templates^®) for Breast Cancer to reflect the currently published NCCN Guidelines for Breast Cancer Version 4.2021.

• The following NCCN Template^® has been DELETED:
  • BRS26: Trastuzumab
• Changes to the Indication section have been made on the following template:
  • BRS174: Capecitabine/Tucatinib + Trastuzumab
• Emetic Risk has been updated on the following templates:
  • BRS111: Everolimus + Fulvestrant
  • BRS115: Fulvestrant + Palbociclib
  • BRS119: Abemaciclib + Fulvestrant
  • BRS120: Fulvestrant
  • BRS140: Fulvestrant + Trastuzumab
  • BRS147: Fulvestrant + Ribociclib
  • BRS160: Alpelisib + Fulvestrant
  • BRS163: Anastrozole + Fulvestrant
  • BRS164: Fulvestrant + Letrozole
• Changes to the Chemotherapy Regimen section have been made on the following template:
  • BRS37: PACLitaxel + Bevacizumab

NCCN has published the following new and updated NCCN Guidelines with NCCN Evidence Blocks™:

• Histiocytic Neoplasms, Version 1.2021 – New
• Basal Cell Skin Cancer, Version 2.2021 – Updated
• Bladder Cancer, Version 3.2021 – Updated
• Cutaneous Melanoma, Version 2.2021 – Updated
• Esophageal and Esophagogastric Junction Cancers, Version 2.2021 – Updated
• Gastric Cancer, Version 2.2021 – Updated
• Multiple Myeloma, Version 6.2021 – Updated
• Squamous Cell Skin Cancer, Version 1.2021 – Updated

For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Drugs & Biologics Compendium (NCCN Compendium^®), the NCCN Biomarkers Compendium^®, the NCCN Chemotherapy Order Templates (NCCN Templates^®), the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.

To view the NCCN Guidelines for Patients^®, please visit NCCN.org/patientguidelines.

Free NCCN Guidelines apps for iPhone, iPad, and Android devices are now available! Visit NCCN.org/apps.

About NCCN Flash Updates™

NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium^®, and other NCCN Content.

Subscribe to NCCN Flash Updates™

Please note: 1. Third Party Content. The NCCN Content may contain content (such as figures, tables or illustrations) that NCCN licenses from third parties as displayed on NCCN Third Party Content FTP site: ftp://ftp1.nccn.org (To access: user name:content; password is NCCNcontent) (“Third Party Content”). Licensee shall be solely responsible for obtaining permissions from each such third party to use any such Third Party Content in the Permitted Works.

Access information on permissions and licensing of NCCN Content

Users may unsubscribe from Flash Updates at any time contacting us. NOTE: The subscription fee for NCCN Flash Updates™ is non-refundable.